New BPEI preclinical data address treatment protocol, corneal biochemical environment, fungal resistance mechanism, MRSA biofilm inhibition, and enhanced cysticidal activity
St. Jude Children’s Research Hospital® and ALSAC, its fundraising and awareness organization, announced today the election and re-election of Board officers for a one-year term beginning July 1.
Securian Financial today announced the elections of Stephanie Lundquist and D. Bryan Jordan to its board of directors, further strengthening the company’s governance with two accomplished leaders who bring deep expertise in human capital strategy, financial services and corporate leadership.
Qventus’ Surgical Growth Solution secured 220 additional surgical cases per month, achieving break-even across all sites in less than three months
Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) on January 30, 2026 for the New Drug Application (NDA)… Read More
New data will be presented about Precise® Molecular Residual Disease (MRD) Test and MyRisk® Hereditary Cancer Test
Lumosa Therapeutics (Lumosa; 6535.TWO) today announced positive results from its Phase 2b clinical trial (LT3001-202) evaluating LT3001 (intravenous Odatroltide) in patients with acute ischemic stroke.
The council unites leading scientists, clinicians, and advocates to ensure that cutting-edge research and lived experience together shape the future of mental health care.
